scispace - formally typeset
Journal ArticleDOI

A Comparative assessment of Metabolic Syndrome and its association with Vitamin D and other risk factors in Type 2 Diabetes Mellitus Patients

TLDR
The study revealed high prevalence rate of metabolic syndrome among type 2 diabetic patients, which was highest according to IDF and lowest was observed in WHO criteria 48.1%.
Abstract
OBJECTIVES To determine the overall prevalence of metabolic syndrome using the World Health Organization (WHO); National Cholesterol Education Program (NCEP), and the International Diabetes Federation (IDF) guidelines and to study its association with vitamin D and other biochemical parameters in patients with type 2 Diabetes mellitus, as well as to identify the set of biochemical parameters that jointly influence the metabolic syndrome using different diagnostic criteria. METHODS A cross-sectional study was carried out at a private health care center in -a total of 291 diabetic patients. Socio-demographic, clinical, and laboratory data were obtained from the medical records of patients. Statistical analysis was carried out using the Statistical Package for the Social Sciences (SPSS, version 23). RESULTS A total number of 291 patients with T2DM were included in this study. The overall prevalence of metabolic syndrome among the study subjects was 48.1%, 87.3%, 64.9% using the WHO, IDF, and NCEP-ATPIII criteria, respectively. The highest prevalence was reported following IDF diagnostic criteria. Sex, triglyceride, and fasting blood sugar were associated factors of metabolic syndrome by all the three diagnostic criteria of metabolic syndrome. CONCLUSION The study revealed a high prevalence rate of metabolic syndrome among type 2 diabetic patients, which was highest at 87.3% according to IDF and lowest was observed according to the WHO criteria i.e, 48.1%. A significant variance in the prevalence of metabolic syndrome was reported between WHO, IDF, and NCEP criteria.

read more

Citations
More filters
Journal ArticleDOI

In vivo and in vitro studies of Danzhi Jiangtang capsules against diabetic cardiomyopathy via TLR4/MyD88/NF-κB signaling pathway

TL;DR: In this article, the Danzhi Jiangtang capsule (DJC) was used for preventing and treating diabetic cardiomyopathy (DCM) in a rat model and the results showed that DJC effectively improved cardiac function, alleviated the pathological changes, and reduced the apoptosis rate.
Related Papers (5)